300 results found.

Diabetes, or Diabetes Mellitus, Type 2 Clinical Trial using insulin degludec; insulin glargine

Novo Nordisk - Recruiting 18 years or older.
- A Randomised, Double Blind, Cross-over Trial Comparing the Safety and Efficacy of Insulin Degludec and Insulin Glargine, With or Without OADs in Subjects With Type 2 Diabetes (SWITCH 2).
insulin degludec; insulin glargine

Type 2 Diabetes Clinical Trial using Insulin glargine/lixisenatide HOE901/AVE0010; Insulin glargine HOE901; Metformin

Sanofi - Recruiting 18 years or older.
- A Randomized, 30-week, Active-controlled, Open Label, 2- Treatment Arm, Parallel-group, Multicenter Study Comparing the Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination to Insulin Glargine With or Without Metformin in Patients With T2DM.
Insulin glargine/lixisenatide HOE901/AVE0010; Insulin glargine HOE901; Metformin

Type 2 Diabetes Clinical Trial using MK-3102; Sitagliptin; Placebo to MK-3102; Placebo to Sitagliptin; Open-label Metformin; Open-label Glimepiride

Merck Sharp & Dohme Corp. - Recruiting 18 years or older.
- A Phase III, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Sitagliptin in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin.
MK-3102; Sitagliptin; Placebo to MK-3102; Placebo to Sitagliptin; Open-label Metformin; Open-label Glimepiride

Type 2 Diabetes Mellitus Clinical Trial using MK-3102; Placebo

Merck Sharp & Dohme Corp. - Recruiting 40 years or older.
- A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess Cardiovascular Outcomes Following Treatment With MK-3102 in Subjects With Type 2 Diabetes Mellitus.
MK-3102; Placebo

Diabetes, or Diabetes Mellitus, Type 2 Clinical Trial using insulin degludec; insulin glargine

Novo Nordisk - Recruiting 50 years or older.
- A Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Subjects With Type 2 Diabetes at High Risk of Cardiovascular Events.
insulin degludec; insulin glargine

Diabetes Mellitus, Type 2 Clinical Trial using Trazenta

Boehringer Ingelheim - Recruiting N/A or older.
- Post Marketing Surveillance on Long Term Drug Use of Trazentar Tablets as add-on Therapy in Patients With Type 2 Diabetes Mellitus.
Trazenta

Type 2 Diabetes Mellitus Clinical Trial using Exenatide Once Weekly; Placebo

Bristol-Myers Squibb - Recruiting 18 years or older.
- Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL). A Randomized, Placebo Controlled Clinical Trial to Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly in Patients With Type 2 Diabetes Mellitus..
Exenatide Once Weekly; Placebo

Diabetes Mellitus, Type 2 Clinical Trial using Canagliflozin 100 mg; Canagliflozin 50 mg; Canagliflozin 300 mg; Placebo

Janssen Research & Development, LLC - Recruiting 10 years to 17 years.
- Open-Label, Multicenter, Multiple Oral Dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents ò10 to <18 Years of Age With Type 2 Diabetes Mellitus and Currently on a Stable Dose of Metformin.
Canagliflozin 100 mg; Canagliflozin 50 mg; Canagliflozin 300 mg; Placebo

Type 2 Diabetes Mellitus Clinical Trial using MK-3102; Matching placebo to MK-3012; Glimepiride; Metformin

Merck Sharp & Dohme Corp. - Recruiting 18 years or older.
- A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial to Study the Safety and Efficacy of the Addition of MK-3102 to Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Combination Therapy With Glimepiride and Metformin.
MK-3102; Matching placebo to MK-3012; Glimepiride; Metformin

Type 2 Diabetes Mellitus Clinical Trial using Ertugliflozin (5 mg); Ertugliflozin (10 mg); Placebo to Ertuglifozin; Metformin; Placebo to Metformin

Merck Sharp & Dohme Corp. - Recruiting 18 years or older.
- A Phase 3, Randomized, Double-blind, Placebo-controlled, 26-week Multicenter Study With a 26-Week Extension to Evaluate the Efficacy and Safety of Ertugliflozin Monotherapy in the Treatment of Subjects With Type 2 Diabetes Mellitus and Inadequate Glycemic Control Despite Diet and Exercise.
Ertugliflozin (5 mg); Ertugliflozin (10 mg); Placebo to Ertuglifozin; Metformin; Placebo to Metformin

Type 2 Diabetes Mellitus Clinical Trial using MK-3102; Placebo to MK-3102; Glipizide; Placebo to glipizide; Insulin

Merck Sharp & Dohme Corp. - Recruiting 30 years or older.
- A Phase III, Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy and Safety of MK-3102 Versus Placebo in Subjects With Type 2 Diabetes Mellitus With Moderate or Severe Chronic Kidney Disease or Kidney Failure on Dialysis Who Have Inadequate Glycemic Control.
MK-3102; Placebo to MK-3102; Glipizide; Placebo to glipizide; Insulin

Diabetes Mellitus, Type 2 Clinical Trial using Metformin; Sitagliptin / Metformin; Placebo to Metformin; Placebo to Sitagliptin / Metformin

Merck Sharp & Dohme Corp. - Recruiting 10 years to 17 years.
- A Phase III, Multicenter, Double-Blind, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-0431A (A Fixed-Dose Combination Tablet of Sitagliptin and Metformin) in Pediatric Patients With Type 2 Diabetes Mellitus.
Metformin; Sitagliptin / Metformin; Placebo to Metformin; Placebo to Sitagliptin / Metformin

Type 2 Diabetes Mellitus Clinical Trial using MK-0431A XR; Placebo to MK-0431A XR; Metformin XR; Placebo to metformin XR; Insulin glargine

Merck Sharp & Dohme Corp. - Recruiting 10 years to 17 years.
- A Phase III Multicenter, Double-blind, Randomized, Placebo-controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-0431A XR (a Fixed-dose Combination Tablet of Sitagliptin and Extended-release Metformin) in Pediatric Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy.
MK-0431A XR; Placebo to MK-0431A XR; Metformin XR; Placebo to metformin XR; Insulin glargine

Diabetes Mellitus, or Glucose Intolerance Clinical Trial

National Taiwan University Hospital - Recruiting 18 years or older.
- Effects of Pancreaticoduodenectomy on Glucose Metabolism.

Type 2 Diabetes Clinical Trial using Paricalcitol; placebo

Mario Negri Institute for Pharmacological Research - Recruiting 18 years to 80 years.
- A Prospective, Randomized, Cross-over, Double-blind, Placebo-controlled Study to Assess the Antiproteinuric Effect of Selective Vitamin d Receptor Activation by Paricalcitol in Type 2 Diabetes Patients on Low or High Sodium Diet and Stable Ras Inhibitor Therapy.
Paricalcitol; placebo

Type 2 Diabetes, or Obesity Clinical Trial using Calorie restriction (25%); Ad libitum health diet

Mario Negri Institute for Pharmacological Research - Recruiting 40 years or older.
- LONG-TERM EFFECTS OF CALORIC RESTRICTION ON METABOLIC, RENAL AND RETINAL HEALTH IN SUBJECTS AFFECTED BY OBESITY AND TYPE 2 DIABETES.
Calorie restriction (25%); Ad libitum health diet

Phone Cognitive Behavioral Therapy, or Smartphone App Clinical Trial using CBT; Smartphone app; Standard Diabetes Care at PCP

University of Pittsburgh - Recruiting 30 years to 65 years.
- mHealth Skill Enhancement Plus Phone CBT for Type 2 Diabetes Distress Medication Nonadherence: Pilot Study.
CBT; Smartphone app; Standard Diabetes Care at PCP

Diabetes Mellitus, Type 2 Clinical Trial using Linagliptin; Empagliflozin + Linagliptin; Empaglifozin placebo + Linagliptin placebo

Boehringer Ingelheim - Recruiting 18 years or older.
- A Phase III, Randomised, Double-blind, Parallel Group, 24 Week Study to Evaluate Efficacy and Safety of Once Daily Empagliflozin 10 mg and 25 mg Compared to Placebo, All Administered as Oral Fixed Dose Combinations With Linagliptin 5 mg, in Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control After 16 Weeks Treatment With Linagliptin 5 mg Once Daily on Metformin Background Therapy..
Linagliptin; Empagliflozin + Linagliptin; Empaglifozin placebo + Linagliptin placebo

Diabetes Mellitus, Type 2 Clinical Trial using Trajenta duo

Boehringer Ingelheim - Recruiting 18 years or older.
- A Regulatory Requirement Non Interventional Study to Monitor the Safety and Effectiveness of Trajenta Duo® (Linagliptin/Metformin HCl, 2.5 mg/500 mg, 2.5 mg/850 mg and 2.5 mg/1000 mg, b.i.d) in Korean Patients With Type 2 Diabetes Mellitus.
Trajenta duo

Diabetes Mellitus, Type 2 Clinical Trial using Trajenta tablet

Boehringer Ingelheim - Recruiting 19 years or older.
- A Regulatory Requirement Non Interventional Study to Monitor the Safety and Effectiveness of Trajenta (Linagliptin, 5 mg, q.d) in Korean Patients With Type 2 Diabetes Mellitus(SELINA Study).
Trajenta tablet

Diabetes Mellitus, Type 2, or Healthy Clinical Trial using Empagliflozin; BI 10773

Boehringer Ingelheim - Recruiting 18 years to 70 years.
- An Open-label Mechanistic Study to Examine the Effect of Oral Empagliflozin (25 mg q.d.) on Kinetics of Renal Glucose Reabsorption in Patients With Type 2 Diabetes Mellitus and Healthy Controls.
Empagliflozin; BI 10773

Diabetes Mellitus, Type 1 Clinical Trial using Empagliflozin medium placebo; Empagliflozin low placebo; Empagliflozin high placebo; Empagliflozin medium; Empagliflozin low; Empagliflozin high

Boehringer Ingelheim - Recruiting 18 years to 65 years.
- A 28-day Randomised, Placebo-controlled, Double-blind Parallel Group Phase IIa Trial to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Once Daily Oral Doses of 2.5 mg, 10 mg, and 25 mg Empagliflozin as Adjunctive to Insulin in Patients With Type 1 Diabetes Mellitus (EASE-2).
Empagliflozin medium placebo; Empagliflozin low placebo; Empagliflozin high placebo; Empagliflozin medium; Empagliflozin low; Empagliflozin high

Diabetes Mellitus, Type 2 Clinical Trial using Placebo; Linagliptin 5mg

Boehringer Ingelheim - Recruiting 18 years to 80 years.
- A Phase IIIb, Multicenter, Multinational, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Evaluate the Glycemic and Renal Efficacy of Once Daily Administration of Linagliptin 5 mg for 24 Weeks in Type 2 Diabetes Patients, With Micro- or Macroalbuminuria (30-3000mg/g Creatinine) on Top of Current Treatment With Angiotensin ConvEnzyme Inhibitor or Angiotensin Receptor Blocker - MARLINA (Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin).
Placebo; Linagliptin 5mg

Diabetes Mellitus, Type 2 Clinical Trial using OAD; Trazenta

Boehringer Ingelheim - Recruiting N/A or older.
- Post Marketing Surveillance on Long Term Drug Use of Trazenta® Tablets in Patients With Type 2 Diabetes Mellitus.
OAD; Trazenta

Diabetes Mellitus, Type 2 Clinical Trial using BI 10773; BI 10773 Placebo; BI 10773 / BI 1356; BI 10773 / BI 1356 Placebo

Boehringer Ingelheim - Recruiting 18 years or older.
- A Phase III, Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Linagliptin 5 mg Compared to Placebo, Administered as Oral Fixed Dose Combination With Empagliflozin 10 mg or 25 mg for 24 Weeks, in Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control After 16 Weeks of Treatment With Empagliflozin 10 mg or 25 mg on Metformin Background Therapy.
BI 10773; BI 10773 Placebo; BI 10773 / BI 1356; BI 10773 / BI 1356 Placebo

Autoantibody Positive, Non-diabetic Relatives at Risk for Type 1 Clinical Trial using Teplizumab

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) - Recruiting 8 years to 45 years.
- AntiCD3 Mab (Teplizumab) For Prevention of Diabetes In Relatives At-Risk for Type 1 Diabetes Mellitus.
Teplizumab

Diabetes Mellitus, Type 2 Clinical Trial using Placebo; Linagliptin

Boehringer Ingelheim - Recruiting 18 years or older.
- CARMELINA: A Multicenter, International, Randomized, Parallel Group, Double-blind, Placebo-controlled, Cardiovascular Safety and Renal Microvascular Outcome Study With Linagliptin, 5 mg Once Daily in Patients With Type 2 Diabetes Mellitus at High Vascular Risk.
Placebo; Linagliptin

Diabetes Mellitus, Type 2, or Hyperglycemia Clinical Trial using Empagliflozin low dose qd; Metformin 500 mg bid; Metformin 1000 mg bid; Empagliflozin high dose qd; Empagliflozin low dose bid; Empagliflozin high dose bid

Boehringer Ingelheim - Recruiting 18 years or older.
- A 24-week Phase III Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Twice Daily Oral Administration of Empagliflozin + Metformin Compared With the Individual Components of Empagliflozin or Metformin in Drug Naive Patients With Type 2 Diabetes Mellitus.
Empagliflozin low dose qd; Metformin 500 mg bid; Metformin 1000 mg bid; Empagliflozin high dose qd; Empagliflozin low dose bid; Empagliflozin high dose bid

Diabetes Mellitus, Type 2 Clinical Trial using placebo; BI1356 low dose; BI1356 high dose

Boehringer Ingelheim - Recruiting 10 years to 17 years.
- A Randomised, Double-blind, Placebo-controlled, Parallel Group Dose-finding Study of Linagliptin (1 and 5 mg Administered Orally Once Daily) Over 12 Weeks in Children and Adolescents, From 10 to 17 Years of Age, With Type 2 Diabetes Mellitus.
placebo; BI1356 low dose; BI1356 high dose

Type 1 Diabetes Mellitus Clinical Trial using Secukinumab; Placebo

Novartis - Recruiting 8 years to 35 years.
- A Randomized, Double-blind, Multiple Dose, Placebo-controlled Study to Evaluate the Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Efficacy of Secukinumab in Adult and Pediatric Patients With New-onset Type 1 Diabetes Mellitus (T1D).
Secukinumab; Placebo

Exocrine Pancreatic Insufficiency in Subjects With Diabetes Melli Clinical Trial using Creon; Creon 25000 matching Placebo

Abbott - Recruiting 30 years or older.
- A Double-blind, Randomized, Multi-center, Placebo-controlled, Parallel-group Study to Assess the Effect of Creonr on Pancreatic Exocrine Insufficiency in Subjects With Diabetes Mellitus Type 2.
Creon; Creon 25000 matching Placebo

Cystoid Macular Edema, Cataract, or Diabetes Mellitus Clinical Trial using Bromfenac; Dexamethasone; Bevacizumab; Triamcinolone Acetonide

Maastricht University Medical Center - Recruiting 21 years or older.
- PRevention of Macular EDema After Cataract Surgery.
Bromfenac; Dexamethasone; Bevacizumab; Triamcinolone Acetonide

Brief CBT, or Smart-phone App Clinical Trial using Brief CBT

University of Pittsburgh - Recruiting 30 years to 65 years.
- Brief CBT Interventions Delivered by Nurse Care Managers to Improve Type 2 Diabetes Outcomes: Pilot Study.
Brief CBT

Type 2 Diabetes Clinical Trial using HM11260C; Placebo

Hanmi Pharmaceutical Company Limited - Recruiting 18 years to 74 years.
- A Phase II, 16-week, Double-blind, Placebo-controlled, Parallel-group, Randomised, Multicentre Trial to Assess Effect on Glycaemic Control of Three Doses of HM11260C in Subjects With Inadequately Controlled Type 2 Diabetes Receiving a Stable Dose of Metformin.
HM11260C; Placebo

Type 2 Diabetes in Obese Subjects Clinical Trial using EndoBarrier; Sham Procedure

GI Dynamics - Recruiting 21 years to 65 years.
- A Randomized, Multi-Center, Pivotal Efficacy and Safety Study Comparing the EndoBarrier Gastrointestinal Liner System vs. Sham for Glycemic Improvement in Inadequately Controlled Obese Type 2 Diabetic Subjects on Oral Anti-Diabetes Agents.
EndoBarrier; Sham Procedure

Diabetes, or Diabetes Mellitus, Type 1 Clinical Trial using insulin degludec; insulin glargine; insulin aspart

Novo Nordisk - Recruiting 18 years or older.
- A Randomised, Double Blind, Cross-over Trial Comparing the Safety and Efficacy of Insulin Degludec and Insulin Glargine, Both With Insulin Aspart as Mealtime Insulin in Subjects With Type 1 Diabetes (BEGIN™: Switch 1).
insulin degludec; insulin glargine; insulin aspart

Diabetes Mellitus Clinical Trial

Fundacion para la Investigacion y Formacion en Ciencias de la Salud - Recruiting 34 years to 75 years.
- Central and Peripheral Blood Pressure and Its Relation With Vascular Target Organ Damage in Carotid, Retinal and Arterial Stiffness. Developed and Validation of a Tool.

Colorectal Cancer, Breast Cancer, Coronary Heart Disease, or Diab Clinical Trial using risk assessment survey; decision support for providers for prevention based on risk

Brigham and Women's Hospital - Recruiting 18 years to 75 years.
- Health Information Technology (HIT) Enhanced Family History Documentation and Management in Primary Care.
risk assessment survey; decision support for providers for prevention based on risk

Branched-chain Amino Acid Metabolism, or Insulin Sensitivity Clinical Trial using Pre-Diabetes Group - 6-mo Aerobic and Resistance combined exercise training; GBP Group - Non-diabetics intending to undergo Gastric Bypass surgery

Duke University - Recruiting 30 years to 65 years.
- Regulation of Branched-chain Amino Acid Metabolism in Pre-Diabetes: Responses to Exercise Training and Gastric Bypass Surgery.
Pre-Diabetes Group - 6-mo Aerobic and Resistance combined exercise training; GBP Group - Non-diabetics intending to undergo Gastric Bypass surgery

Gestational Diabetes Mellitus, or Pregnancy Clinical Trial using Lifestyle Counseling

University of North Carolina, Chapel Hill - Recruiting 21 years to 35 years.
- A Transgenerational e-Intervention for Gestational Diabetics and Their Offspring: A Pilot Trial.
Lifestyle Counseling

Type 2 Diabetes Clinical Trial using DIAMOND System

Metacure - Recruiting 18 years to 70 years.
- The DIAMOND® for the Treatment of Type 2 Diabetes: Can Blood Triglycerides Level be the Predictor for Therapy Efficiency A Multicentre, Prospective, Semi-randomized Study.
DIAMOND System

Essential Hypertension Complicated by Type 2 Diabetes Mellitus Clinical Trial using Azilsartan; Telmisartan

Takeda - Recruiting 20 years or older.
- A Study to Explore the Effects of Azilsartan Compared to Telmisartan on Insulin Resistance of Patients With Essential Hypertension on Type 2 Diabetes Mellitus by HOMA-R.
Azilsartan; Telmisartan

Hypoglycemia Clinical Trial using G-Pen Mini™ (glucagon injection)

Xeris Pharmaceuticals - Recruiting 18 years to 30 years.
- A Randomized, Phase 2a, Blinded, 3-Way Crossover Dose-Ranging Study With G-Pen Mini™ (Glucagon Injection) to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Patients With Type 1 Diabetes Mellitus (T1DM).
G-Pen Mini™ (glucagon injection)

Gestational Diabetes Mellitus Clinical Trial using myo-inositol

University of Messina - Recruiting 18 years to 44 years.
- Effect of Myo-inositol Administration on Insulin Sensitivity in Gestational Diabetes Patients by Continuous Glucose Monitoring System (CGMS).
myo-inositol

Biliary Atresia Clinical Trial

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) - Recruiting 1 year to 75 years.
- Biliary Atresia Study in Infants and Children (BASIC).

Lower Extremity Chronic Ulcers in Diabetics Clinical Trial using CureXcellr; Sham injection

Macrocure Ltd. - Recruiting 18 years or older.
- A Phase III Multicenter, Randomized, Double-Blind, Parallel-Group, Sham-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of CureXcellr as an Adjunct to Good Wound Care in Lower Extremity Chronic Ulcers in Adults With Diabetes Mellitus.
CureXcellr; Sham injection

Diabetes, or Healthy Clinical Trial using semaglutide; placebo; moxifloxacin

Novo Nordisk - Recruiting 18 years to 45 years.
- A Thorough QTc Evaluation of the Effect of Semaglutide on Cardiac Repolarisation in Healthy Subjects: A Randomised, Double-Blind,Placebo-Controlled, Three-Arm Parallel Trial With a Nested Cross-Over Design for Positive Control With Moxifloxacin Administration.
semaglutide; placebo; moxifloxacin

Diabetes, or Diabetes Mellitus, Type 1 Clinical Trial using liraglutide; placebo

Novo Nordisk - Recruiting 18 years to 75 years.
- The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes. A 52-week Randomised, Treat-to-target, Placebo-controlled, Double Blinded, Parallel Group, Multinational, Multi-centre Trial.
liraglutide; placebo

Diabetes, or Diabetes Mellitus, Type 2 Clinical Trial using semaglutide; exenatide

Novo Nordisk - Recruiting 18 years or older.
- Efficacy and Safety of Semaglutide Once-weekly Versus Exenatide ER 2.0 mg Once-weekly as add-on to 1-2 Oral Antidiabetic Drugs (OADs) in Subjects With Type 2 Diabetes (SUSTAINT 3 - vs. QW GLP-1).
semaglutide; exenatide

Type 2 Diabetes Mellitus Clinical Trial using DIAMOND System

Metacure - Recruiting 21 years to 70 years.
- An Advanced Configuration (The Third Generation) of the DIAMOND System for the Treatment of T2DM Patients - A Randomized, Double Blind Study.
DIAMOND System

Type 1 Diabetes, or Type 2 Diabetes Clinical Trial using No treatment

Abbott Diabetes Care - Recruiting 18 years or older.
- Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System.
No treatment

Chronic Pancreatitis, or Diabetes Mellitus Clinical Trial using Closed Loop Insulin

University of Minnesota - Clinical and Translational Science Institute - Recruiting 21 years to 64 years.
- Efficacy and Feasibility of Fully Automated Closed Loop Insulin Pump Therapy After Islet Auto-Transplantation.
Closed Loop Insulin

Diabetes, Gestational, or Diabetes, Type 2 Clinical Trial using Insulin

St. Luke's-Roosevelt Hospital Center - Recruiting 18 years or older.
- Insulin Detemir Versus Insulin NPH: A Randomized Prospective Study Comparing Glycemic Control in Pregnant Women With Diabetes.
Insulin

Pedal Pad Atrophy, or Diabetes Mellitus Clinical Trial using Year A Pathway; Year B Pathway

University of Pittsburgh - Recruiting 18 years or older.
- Fat Grafting for Pedal Fat Pad Atrophy in Diabetics.
Year A Pathway; Year B Pathway

Diabetic Foot Ulcers Clinical Trial using DSC127; placebo vehicle gel

Derma Sciences, Inc. - Recruiting 18 years or older.
- A Randomized, Double-blind, Parallel-group, Vehicle-controlled Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of DSC127 in Treating Non-healing Foot Ulcers in Subjects With Diabetes Mellitus.
DSC127; placebo vehicle gel

Type 2 Diabetes Mellitus, or Cardiovascular Disease Clinical Trial using Liraglutide; Sitagliptin

University of Leicester - Recruiting 18 years to 50 years.
- Impact of Liraglutide on Cardiac Function and Structure in Young Adults With Type 2 Diabetes: an Open-label, Randomised Active-comparator Trial.
Liraglutide; Sitagliptin

Diabetes Clinical Trial

Assistance Publique - H“pitaux de Paris - Recruiting 18 years to 65 years.
- Devenir au Long Cours de la Cellule bˆta Chez Les Adultes Porteurs d'Anomalies g‚n‚tiques … l'Origine du DiabŠte N‚onatal.

Diabetes Mellitus, Type 2, or Albuminuria Clinical Trial using Placebo; Canagliflozin, 100 mg; Canagliflozin, 300 mg

Janssen Research & Development, LLC - Recruiting 30 years or older.
- A Randomized, Multicenter, Double-Blind, Parallel, Placebo-Controlled Study of the Effects of Canagliflozin on Renal Endpoints in Adult Subjects With Type 2 Diabetes Mellitus.
Placebo; Canagliflozin, 100 mg; Canagliflozin, 300 mg

Type 1 Diabetes Clinical Trial using contingency management

University of Connecticut Health Center - Recruiting 15 years to 21 years.
- A Pilot Study Examining a Reinforcement Approach to Improve Diabetes Management.
contingency management

Diabetes Mellitus, Type 1 Clinical Trial using dietary intervention

Helsinki University - Recruiting N/A to 12 Months.
- Early Dietary Intervention and Later Signs of Beta-Cell Autoimmunity: Potential Mechanisms.
dietary intervention

Heart Failure Clinical Trial using BAY94-8862; Eplerenone; Placebo

Bayer - Recruiting 18 years or older.
- A Randomized, Double-blind, Double-dummy, Multi-center Study to Assess Safety and Efficacy of BAY94-8862 in Japanese Subjects With Emergency Presentation at the Hospital Because of Worsening Chronic Heart Failure With Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Moderate Chronic Kidney Disease Alone Versus Eplerenone.
BAY94-8862; Eplerenone; Placebo

Type 2 Diabetes Mellitus Clinical Trial using Ertugliflozin 5 mg; Ertugliflozin 15 mg; Placebo to Ertugliflozin; Glimepiride; Placebo to Glimepiride; Basal Insulin; Metformin

Merck Sharp & Dohme Corp. - Recruiting 18 years or older.
- A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 26-Week Multicenter Study With a 78-Week Extension To Evaluate The Efficacy And Safety Of Ertugliflozin In Subjects With Type 2 Diabetes Mellitus And Inadequate Glycemic Control On Metformin Monotherapy.
Ertugliflozin 5 mg; Ertugliflozin 15 mg; Placebo to Ertugliflozin; Glimepiride; Placebo to Glimepiride; Basal Insulin; Metformin

Diabetes Mellitus, Type 2 Clinical Trial using Ticagrelor 90 mg; Ticagrelor placebo

AstraZeneca - Recruiting 50 years or older.
- A Multinational, Randomised, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Ticagrelor 90 mg Twice Daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Stroke in Patients With Type 2 Diabetes Mellitus (THEMIS - Effect of Ticagrelor on Health Outcomes in diabEtes Mellitus Patients Intervention Study).
Ticagrelor 90 mg; Ticagrelor placebo

Diabetes Mellitus, or Insulin Resistance Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting N/A or older.
- Studies of Molecular Genetics of Insulin Secretion, Insulin Action, and Diabetes Mellitus.

Diabetes Mellitus, or Obesity Clinical Trial using Oral glucose tolerance test

National Institutes of Health Clinical Center (CC) - Recruiting 19 years to 65 years.
- Inhibition of Intestinal Glucose Absorption by the Bioflavonoid Quercetin in the Obese and in Obese Type 2 Diabetics.
Oral glucose tolerance test

Morbid Obesity, Diabetes Mellitus Type 2, Insulin Resistance, Obs Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- Study of the Phenotype of Overweight and Obese Adults.

Diabetes, or Diabetes Mellitus, Type 2 Clinical Trial using insulin aspart (FIAsp); insulin aspart; insulin glargine

Novo Nordisk - Recruiting 18 years or older.
- Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes.
insulin aspart (FIAsp); insulin aspart; insulin glargine

Type 1 Diabetes, Type 2 Diabetes, Immunologically Mediated Type 1 Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 2 years or older.
- Natural History of Autoimmune Diabetes and Its Complications.

Diabetes, Cancer, or Cardiovascular Disease Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- Development of the Family Map: Examination of Communal Coping Across Disease Context.

Type 1 Diabetes, or Hypoglycemia Unawareness Clinical Trial using Naltrexone

University of Minnesota - Clinical and Translational Science Institute - Recruiting 18 years to 65 years.
- Study of the Effect of Naltrexone on Cerebral Blood Flow and Hypoglycemia in Type 1 Diabetes Mellitus.
Naltrexone

Depression, or Impaired Glucose Tolerance Clinical Trial using The Blues Program; Hey Durham

National Institutes of Health Clinical Center (CC) - Recruiting 12 years to 17 years.
- Mood and Insulin Resistance in Adolescents At-Risk for Diabetes.
The Blues Program; Hey Durham

Diabetes, Cancer, or Heart Disease Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- The Role of the Family Genetics Health Educator in Influencing Health Promoting Behaviors.

Diabetes, Diabetic Foot Ulcer Clinical Trial using MatriStem; Cellular Dermal Replacement Tissue

ACell Inc. - Recruiting 18 years to 85 years.
- An Evaluation of Tissue Engineering Approaches for Treatment of Neuropathic Diabetic Foot Ulcers Resistant to Standard of Care: A Prospective, Randomized Controlled Trial.
MatriStem; Cellular Dermal Replacement Tissue

Type 1 Diabetes, or Hypoglycemia Unawareness Clinical Trial using somatostatin

University of Minnesota - Clinical and Translational Science Institute - Recruiting 18 years to 65 years.
- Measurement of Glucose Metabolism in Humans Using Magnetic Resonance at 4 Tesla. Substudy: Hypoglycemia Unawareness.
somatostatin

Asthma, Diabetes, Obesity, Premature Birth, or Autistic Disorder Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting N/A or older.
- Vanguard Phase of the National Children s Study.

Diabetes, or Cardiovascular Disease Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- Genetics of Obesity, Diabetes, and Heart Disease in African Diaspora Populations.

Obesity, Diet Therapy, or Diabetes Type 2 Clinical Trial using Controlling Gestational Weight Gain

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- Lifestyle Interventions for Expectant Moms (LIFE-Moms Phoenix)-Phoenix.
Controlling Gestational Weight Gain

Prediabetes, or Type 2 Diabetes Clinical Trial using Vitamin D (Cholecalciferol); Placebo

Tufts Medical Center - Recruiting 30 years or older.
- Vitamin D and Type 2 Diabetes Study.
Vitamin D (Cholecalciferol); Placebo

Diabetes Mellitus, Type 1 Clinical Trial

Yale University - Recruiting 10 years to 37 years.
- ITN0127AI Autoimmunity-blocking Antibody for Tolerance in Recently Diagnosed Type 1 Diabetes (AbATE) Follow-Up Study.

Type 2 Diabetes Clinical Trial using lixisenatide (AVE0010); placebo

Sanofi - Recruiting 70 years or older.
- A Randomized, Double-blind, Placebo-controlled, 2-arm Parallel-group, Multicenter, 24 Week Study Assessing the Safety and Efficacy of Lixisenatide in Older Patients With Type 2 Diabetes Inadequately Controlled on Their Current Diabetes Treatment Regimen.
lixisenatide (AVE0010); placebo

Type 2 Diabetes Mellitus Clinical Trial using Lixisenatide (AVE0010); Placebo

Sanofi - Recruiting 10 years to 65 years.
- A Randomized, Double-blind, Placebo Controlled Trial to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Lixisenatide in Paediatric (10 - 17 Years Old) and Adult Patients With Type 2 Diabetes.
Lixisenatide (AVE0010); Placebo

Type 2 Diabetes Mellitus Clinical Trial using lixisenatide AVE0010

Sanofi - Recruiting 20 years or older.
- An Open-label, Multicenter 24-Week And 52-Week Study Assessing The Safety And Tolerability Of Lixisenatide In Monotherapy In Patients With Type 2 Diabetes.
lixisenatide AVE0010

Type 2 Diabetes Mellitus Clinical Trial using Lixisenatide (AVE0010); Placebo

Sanofi - Recruiting 18 years or older.
- A Randomized, Double-blind, Placebo-controlled, 2-arm Parallel-group, Multicenter Study With a 24-week Treatment Period Assessing the Efficacy and Safety of Lixisenatide in Patients With Type 2 Diabetes Insufficiently Controlled With Basal Insulin With or Without Metformin.
Lixisenatide (AVE0010); Placebo

Type 2 Diabetes Clinical Trial using Insulin glargine/lixisenatide HOE901/AVE0010; Insulin glargine HOE901; Lixisenatide AVE0010; Metformin

Sanofi - Recruiting 18 years or older.
- A Randomized, 30 Week, Active-controlled, Open-label, 3-treatment Arm, Parallel-group Multicenter Study Comparing the Efficacy and Safety of Insulin Glargine/ Lixisenatide Fixed Ratio Combination to Insulin Glargine Alone and to Lixisenatide Alone on Top of Metformin in Patients With Type 2 Diabetes Mellitus T2DM.
Insulin glargine/lixisenatide HOE901/AVE0010; Insulin glargine HOE901; Lixisenatide AVE0010; Metformin

Diabetes, or Diabetes Mellitus, Type 2 Clinical Trial using semaglutide; oral placebo

Novo Nordisk - Recruiting 18 years or older.
- Multiple Dose Trial Examining Dose Range, Escalation and Efficacy of Oral Semaglutide in Subjects With Type 2 Diabetes.
semaglutide; oral placebo

Type 2 Diabetes Clinical Trial using lixisenatide (AVE0010); insulin glulisine (HMR1964)

Sanofi - Recruiting 18 years or older.
- A Randomized, Open-label, Active-controlled, 3-arm Parallel-group, 26-week Study Comparing the Efficacy and Safety of Lixisenatide to That of Insulin Glulisine Once Daily and Insulin Glulisine Three Times Daily in Patients With Type 2 Diabetes Insufficiently Controlled With Insulin Glargine With or Without Metformin.
lixisenatide (AVE0010); insulin glulisine (HMR1964)

Type 2 Diabetes Clinical Trial using Liraglutide; diet; Aspirin

Royal Devon and Exeter NHS Foundation Trust - Recruiting 18 years to 70 years.
- Does Glucagon-like Polypeptide 1 Improve Vascular Function and Inflammation?.
Liraglutide; diet; Aspirin

Type 2 Diabetes, or Obesity Clinical Trial using GLP-1; Placebo

Royal Devon and Exeter NHS Foundation Trust - Recruiting 18 years or older.
- The Microvascular Function of GLP-1 and Its Analogues in Humans, in Vivo: the Role of DPP-IV Inhibition.
GLP-1; Placebo

Diabetes Mellitus Type 2, or Hypertension Clinical Trial using Ginseng; Wheat Bran

St. Michael's Hospital, Toronto - Recruiting 40 years to 75 years.
- Efficacy and Safety of Combined Rg3-enriched Korean Red Ginseng (Panax Ginseng C.A. Meyer) and American Ginseng (Panax Quinquefolius) as Poly-therapy in the Management of Concomitant Hypertension in Type 2 Diabetes.
Ginseng; Wheat Bran

Monogenic Diabetes Clinical Trial using GLP-1; Exendin 9-39

University of Chicago - Recruiting 18 years to 89 years.
- Incretin Regulation of Insulin Secretion in Monogenic Diabetes.
GLP-1; Exendin 9-39

Diabetes, or Diabetes Mellitus, Type 1 Clinical Trial using insulin degludec/insulin aspart; insulin aspart; insulin detemir

Novo Nordisk - Recruiting 1 year to 17 years.
- A Trial Investigating the Efficacy and Safety of Insulin Degludec/Insulin Aspart Once Daily Plus Insulin Aspart for the Remaining Meals Versus Insulin Detemir Once or Twice Daily Plus Meal Time Insulin Aspart in Children and Adolescents With Type 1 Diabetes Mellitus.
insulin degludec/insulin aspart; insulin aspart; insulin detemir

Diabetes Mellitus, Type 2 Clinical Trial using PF-06291874; Placebo

Pfizer - Recruiting 18 years to 70 years.
- A Phase 1, Placebo-Controlled Trial To Assess The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Multiple Escalating Oral Doses Of PF-06291874 In Adults With Type 2 Diabetes Mellitus.
PF-06291874; Placebo

Type 2 Diabetes Mellitus, or Obesity Clinical Trial using 13C inulin; Inulin; Placebo

Maastricht University Medical Center - Recruiting 20 years to 50 years.
- SCFA Production and Their Metabolic Effects After Inulin Ingestion.
13C inulin; Inulin; Placebo

Obesity, Morbid, or Diabetes Mellitus Type 2 Clinical Trial

Merck Sharp & Dohme Corp. - Recruiting 20 years to 60 years.
- Gut Hormone Profiling in Peripheral Blood After Bariatric Surgery in Obese Patients With Type 2 Diabetes.

Long-standing Type 1 Diabetes Mellitus Clinical Trial using Beta-Air device for encapsulation of transplanted human islets

Uppsala University Hospital - Recruiting 18 years or older.
- An Open Label, Pilot Investigation, to Assess the Safety and Efficacy of Transplantation of Macro-encapsulated Human Islets Within the Bioartificial Pancreas Beta-Air in Patients With Type 1 Diabetes Mellitus.
Beta-Air device for encapsulation of transplanted human islets

Diabetes Type 1, or Endothelial Dysfunction Clinical Trial using Single pancreas transplantation

Oslo University Hospital - Recruiting 18 years or older.
- Assessment of Cardiovascular Risk Factors, Including Endothelial Function, After Restoration of Normoglycemia Following Single Pancreas Transplantation.
Single pancreas transplantation

Type 2 Diabetes Mellitus Clinical Trial using Telemedical coaching; Telemedicine

West German Center of Diabetes and Health - Recruiting 25 years to 79 years.
- Diabetes Coaching Study.
Telemedical coaching; Telemedicine

Diabetes Clinical Trial using Mozobil

University of Padova - Recruiting 18 years to 65 years.
- Mobilization Test of BM Progenitor Cells With Plerixafor / AMD3100: Controlled Parallel Group Comparison Between Diabetic and Non Diabetic Subjects.
Mozobil

Diabetic Nephropathies Clinical Trial using BAY94-8862; Placebo

Bayer - Recruiting 18 years or older.
- A Randomized, Double-blind, Placebo-controlled, Multi-center Study to Assess the Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy.
BAY94-8862; Placebo

Diabetic Nephropathies Clinical Trial using BAY94-8862; Placebo; BAY 94-8862

Bayer - Recruiting 18 years or older.
- A Randomized, Double-blind, Placebo-controlled, Multi-center Study to Assess the Safety and Efficacy of Different Oral Doses of BAY94-8862 in Japanese Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy.
BAY94-8862; Placebo; BAY 94-8862

Diabetes Mellitus, Type 2 Clinical Trial using Web-based insulin titration

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) - Recruiting 18 years to 80 years.
- Web-based Insulin Titration: Improving Diabetes Care in the Netherlands. An Efficacy Study..
Web-based insulin titration

Type 2 Diabetes Mellitus Clinical Trial using MK-3102; Glimepiride; MK-3102 Placebo; Glimepiride Placebo

Merck Sharp & Dohme Corp. - Recruiting 18 years or older.
- A Phase III, Multicenter, Double-Blind, Randomized Trial to Evaluate the Safety and Efficacy of MK-3102 Compared With Glimepiride in Subjects With Type 2 Diabetes Mellitus For Whom Metformin is Inappropriate Due to Intolerance or Contraindication.
MK-3102; Glimepiride; MK-3102 Placebo; Glimepiride Placebo

Diabetes, or Diabetes Mellitus, Type 2 Clinical Trial using semaglutide; placebo

Novo Nordisk - Recruiting 18 years or older.
- Efficacy and Safety of Semaglutide Once-weekly Versus Placebo in Drug-na‹ve Subjects With Type 2 Diabetes.
semaglutide; placebo

Type 2 Diabetes Mellitus Clinical Trial using Ertugliflozin; Placebo

Merck Sharp & Dohme Corp. - Recruiting 40 years or older.
- Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess Cardiovascular Outcomes Following Treatment With Ertugliflozin (MK-8835/PF-04971729) in Subjects With Type 2 Diabetes Mellitus and Established Vascular Disease.
Ertugliflozin; Placebo

Diabetes Mellitus, Type 2 Clinical Trial using PF-05175157; Placebo

Pfizer - Recruiting 18 years to 65 years.
- A 6-Week Phase 2a Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study To Assess Safety, Tolerability And Pharmacodynamics Of Oral PF-05175157 As Monotherapy In Subjects With Type 2 Diabetes Mellitus.
PF-05175157; Placebo

Type 2 Diabetes Mellitus Clinical Trial using Ertugliflozin; Placebo

Merck Sharp & Dohme Corp. - Recruiting 25 years or older.
- A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Ertugliflozin (MK-8835/PF-04971729) in Subjects With Type 2 Diabetes Mellitus With Stage 3 Chronic Kidney Disease Who Have Inadequate Glycemic Control on Background Antihyperglycemic Therapy.
Ertugliflozin; Placebo

Diabetes Mellitus Clinical Trial using MK-3102; Placebo to MK-3102; Metformin

Merck Sharp & Dohme Corp. - Recruiting 18 years to 44 years.
- A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of MK-3102 in ò18 and <45 Year-Old Subjects With Type 2 Diabetes Mellitus and Inadequate Glycemic Control.
MK-3102; Placebo to MK-3102; Metformin

Type 2 Diabetes Mellitus Clinical Trial using Ertugliflozin; Glimepiride; Placebo to Ertugliflozin; Placebo to Glimepiride; Metformin; Sitagliptin

Merck Sharp & Dohme Corp. - Recruiting 18 years or older.
- A Phase III, Multicenter, Randomized, Double-Blind, Active-Comparator-Controlled Clinical Trial to Study the Safety and Efficacy of the Addition of Ertugliflozin (MK-8835/PF-04971729) Compared With the Addition of Glimepiride in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin.
Ertugliflozin; Glimepiride; Placebo to Ertugliflozin; Placebo to Glimepiride; Metformin; Sitagliptin

Obesity, Insulin Resistance, Overweight, or Diabetes Mellitus, Ty Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 8 years to 25 years.
- Natural History of Type 2 Diabetes Mellitus in Children and Young Adults.

Diabetes, Obesity, or Weight Gain Clinical Trial using Behavioral Weight Loss Program

Department of Veterans Affairs - Recruiting 18 years to 70 years.
- Management of Antipsychotic Medication Associated Obesity - 2.
Behavioral Weight Loss Program

Type 2 Diabetes Mellitus Clinical Trial using Sitagliptin/metformin XR; Placebo

Merck Sharp & Dohme Corp. - Recruiting 10 years to 17 years.
- A Study to Assess the Pharmacokinetics and the Ability for Pediatric Patients With Type 2 Diabetes to Swallow MK-0431A XR Tablets.
Sitagliptin/metformin XR; Placebo

Coronary Artery Disease Clinical Trial

Global Genomics Group, LLC - Recruiting 18 years to 90 years.
- Genetic Loci and the Burden of Atherosclerotic Lesions.

Diabetes Mellitus, Type 1 Clinical Trial using LY2605541; Insulin Glargine

Eli Lilly and Company - Recruiting 18 years to 65 years.
- Assessment of the Effects of LY2605541 on Triglyceride Metabolism, Compared to Insulin Glargine, in Patients With Type 1 Diabetes Mellitus.
LY2605541; Insulin Glargine

Diabetes, or Healthy Clinical Trial using semaglutide

Novo Nordisk - Recruiting 45 years to 64 years.
- A Single Centre, Open Label Trial Investigating the Absorption, Metabolism and Excretion After a Single Subcutaneous Dose of [3H]-Semaglutide in Healthy Male Subjects.
semaglutide

Diabetes, or Hypertension Clinical Trial

University of North Carolina, Chapel Hill - Recruiting 18 years or older.
- A Mixed Methods Approach to the Development and Testing of the Measure of Drug Self-Management (MeDS), an Assessment for Use in Clinical Settings Among English and Spanish-speaking Patients With Hypertension and Diabetes..

Diabetic Foot Ulcers Clinical Trial using DSC127; placebo vehicle gel; Standard of Care gel, Aquasite

Derma Sciences, Inc. - Recruiting 18 years or older.
- A Randomized, Double-Blind, Parallel-group, Vehicle and Standard of Care-controlled Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of DSC127 in Treating Non-healing Foot Ulcers in Subjects With Diabetes Mellitus.
DSC127; placebo vehicle gel; Standard of Care gel, Aquasite

Diabetes Mellitus, Type 2, or Obesity Clinical Trial using Sport; Tocilizumab; Sitagliptin

University of Zurich - Recruiting 18 years to 75 years.
- A Lifestyle Intervention Study Investigating the Role of Interleukin-6 in the Beneficial Effect of Exercise on Beta-cell Function in Obese People and Patients With Type 2 Diabetes.
Sport; Tocilizumab; Sitagliptin

Diabetes Mellitus Type 2 Clinical Trial

GWT-TUD GmbH - Recruiting 18 years or older.
- Evaluation of the Impact of the CONTOURr USB Blood Glucose Monitoring System With Integrated Data Management on Glycaemic Control in Insulin-treated Diabetic Patients.

Type 2 Diabetes Mellitus, or Periodontal Disease Clinical Trial using non-surgical periodontal treatment; Supragingival biofilm control

University of Sao Paulo - Recruiting 30 years to 80 years.
- .
non-surgical periodontal treatment; Supragingival biofilm control

Insulin Resistance, Type 2 Diabetes Mellitus, Obesity, Androgen D Clinical Trial using Acyline; Testosterone 1.62% gel; Letrozole; Placebo gel (for Testosterone 1.62% gel); Placebo pill (for Letrozole)

University of Washington - Recruiting 25 years to 55 years.
- Androgen-mediated Pathways in the Regulation of Insulin Sensitivity in Men.
Acyline; Testosterone 1.62% gel; Letrozole; Placebo gel (for Testosterone 1.62% gel); Placebo pill (for Letrozole)

Type 2 Diabetes Clinical Trial using Sevelamer 1600 mg TID for 7 days; Placebo 1600 mg TID for 7 days

University Hospital, Gentofte, Copenhagen - Recruiting 35 years to 80 years.
- .
Sevelamer 1600 mg TID for 7 days; Placebo 1600 mg TID for 7 days

DIABETES MELLITUS, NONINSULIN-DEPENDENT, 2 (Disorder) Clinical Trial using SMBG

University of North Carolina, Chapel Hill - Recruiting 30 years or older.
- Effect of Glucose Monitoring on Patient and Provider Outcomes in Non-insulin Treated Diabetes.
SMBG

Atrial Fibrillation, Hypertension, Diabetes, Chronic Heart Failur Clinical Trial using Medtronic Reveal XT implantable loop recorder

Medical University of Graz - Recruiting 18 years or older.
- Randomized Controlled Trial to Evaluate Implanted Event Recorders for the First Diagnosis of Atrial Fibrillation in High-risk Patients.
Medtronic Reveal XT implantable loop recorder

Nervous System, Diabetic Kidney Disease, or Diabetes Mellitus, Ty Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- Determinants of Diabetic Nephropathy in American Indians.

Diabetes Mellitus, Type 2, or Hypertension Clinical Trial using Canagliflozin; Placebo

Janssen Scientific Affairs, LLC - Recruiting 18 years to 75 years.
- A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Blood Pressure Reduction With Ambulatory Blood Pressure Monitoring (ABPM), Safety, and Tolerability of Canagliflozin in the Treatment of Subjects With Hypertension and Type 2 Diabetes Mellitus.
Canagliflozin; Placebo

Nephropathy, Retinopathy, Hypertension, Obesity, or Diabetes Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 26 years or older.
- Genetics of Type 2 Diabetes in Diverse Populations.

Type 2 Diabetes Clinical Trial using HM11260C; liraglutide

Hanmi Pharmaceutical Company Limited - Recruiting 18 years to 74 years.
- A Phase II, 12-week, Double-blind, Randomised, Parallel Group, Multi-centre, International Trial to Assess the Effect on Glycaemic Control of Five Doses of HM11260C Versus Placebo or Open-label Liraglutide in Subjects With Type 2 Diabetes.
HM11260C; liraglutide

Abnormal Glucose Tolerance, or Type 1 Diabetes Clinical Trial using CTLA4-Ig (Abatacept); Placebo

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) - Recruiting 6 years to 45 years.
- CTLA4-Ig (Abatacept)for Prevention of Abnormal Glucose Tolerance and Diabetes in Relatives At -Risk for Type 1 Diabetes.
CTLA4-Ig (Abatacept); Placebo

Type-2 Diabetes Mellitus, or Ischemic Heart Disease Clinical Trial

Thebiosignals.com - Recruiting 18 years to 80 years.
- Risk Prediction in Type II Diabetics With Ischemic Heart Disease by Cardiac Autonomic Function.

Islet Cell Transplantation, or Type 1 Diabetes Clinical Trial using Islet cell transplantation

Baylor Research Institute - Recruiting 18 years to 65 years.
- Pancreatic Islet Cell Transplantation - A Novel Approach to Improve Islet Quality and Engraftment.
Islet cell transplantation

Type 2 Diabetes Clinical Trial using Glycemic clamping

Medical College of Wisconsin - Recruiting 21 years or older.
- Adverse Effects of Systemic Hypoglycemia Exposure on Endothelial Function in Humans.
Glycemic clamping

Type 2 Diabetes Clinical Trial using Vildagliptin; Placebo

Centre d'Etudes et de Recherche pour l'Intensification du Traitement du DiabŠte - Recruiting 18 years or older.
- Evaluation of Galvus (Vildagliptin) Efficacy Versus Placebo in Patients With Type 2 Diabetes, Inadequately Controlled by Metformin and Basal Insulin, This One Having Been Properly Titrated..
Vildagliptin; Placebo

Diabetes Mellitus Clinical Trial using Luyxumia versus Lantus

Profil Institut fr Stoffwechselforschung GmbH - Recruiting 18 years or older.
- A Bicentric Open-label, Randomized, Two-parallel-group Study Investigating the Impact of Combined Lantus Insulin Glargine) and Lyxumia(Lixisenatide) on Insulin Secretion and Gastric Emptying in Subjects With Type 2 Diabetes Mellitus Not Adequately Controlled on Diet and Oral Antidiabetic Medication.
Luyxumia versus Lantus

Side Effects of Calcineurin Inhibitors, Renal Toxicity, Hepatic F Clinical Trial using Liver biopsy

Thomas Jefferson University - Recruiting 18 years or older.
- Sirolimus Switching From Calcinurin Inhibitors (CNI) 90 - 180 Days After Liver Transplantation.
Liver biopsy

Diabetes Mellitus, Type 2 Clinical Trial using Modified paleolithic diet and exercise under observation; Modified paleolithic diet and general advice on exercise

Ume† University - Recruiting 30 years to 65 years.
- Diet and Exercise in Type 2 Diabetes - a Randomized Controlled Trial.
Modified paleolithic diet and exercise under observation; Modified paleolithic diet and general advice on exercise

Type 2 Diabetes, Obesity, or Diabesity Clinical Trial using Liraglutide; Duodenal-jejunal bypass liner - Endobarrier device

Sandwell & West Birmingham Hospitals NHS Trust - Recruiting 18 years or older.
- Randomisation to Endoluminal Intestinal Liner Alone Versus With Incretin Analogue in SustainEd Diabesity (REVISE-Diabesity).
Liraglutide; Duodenal-jejunal bypass liner - Endobarrier device

Type 1 Diabetes Clinical Trial using Sensor

Medtronic Diabetes - Recruiting 2 years to 18 years.
- A Performance Evaluation of the EnliteT and Enlite 2 Glucose Sensor to Support a Full 144 Hours (6 Days) of Use in Children.
Sensor

Coronary Artery Disease, or Diabetes Mellitus Type 2 Clinical Trial using Glucagon-Like-Peptide-1/Regadenoson/Perflutren Lipid Microsphere

Mayo Clinic - Recruiting 40 years to 60 years.
- Effects of Hyperglycemia on Myocardial Perfusion in Humans With and Without Type 2 Diabetes: Modulation by Glucagon-Like-Peptide-1.
Glucagon-Like-Peptide-1/Regadenoson/Perflutren Lipid Microsphere

Diabetes Mellitus Type 1 Clinical Trial using Glucometer GM-205

GlucoVista - Recruiting 18 years to 65 years.
- .
Glucometer GM-205

Chronic Kidney Disease, or Type 2 Diabetes Mellitus Clinical Trial using AZD1722; Placebo

Ardelyx - Recruiting 18 years to 80 years.
- An Exploratory Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Design Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of AZD1722 in CKD Patients With Type 2 Diabetes Mellitus and Albuminuria.
AZD1722; Placebo

Type 1 Diabetes Mellitus Clinical Trial using Blood draw

City of Hope Medical Center - Recruiting 18 years or older.
- Detection of Human Beta Cell Death in T1DM by Methylation Specific PCR.
Blood draw

Type 1 Diabetes Clinical Trial using Algorithm ON

Stanford University - Recruiting 8 years to 25 years.
- .
Algorithm ON

Diabetes, or Diabetes Mellitus, Type 2 Clinical Trial using semaglutide; sitagliptin; placebo

Novo Nordisk - Recruiting 18 years or older.
- Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin and/or TZD in Subjects With Type 2 Diabetes (SUSTAINT 2 - vs. DPP-4 Inhibitor).
semaglutide; sitagliptin; placebo

Type 2 Diabetes Clinical Trial using Optimum Lifestyle Intervention; Standard Care

Washington University School of Medicine - Recruiting 30 years to 64 years.
- Diet and Exercise Intervention in Type 2 Diabetes.
Optimum Lifestyle Intervention; Standard Care

Type 1 and 2 Diabetes Clinical Trial using prise de sang; magnetic resonance imaging and magnetic resonance spectroscopy

Centre Hospitalier Universitaire Dijon - Recruiting 18 years or older.
- Genetic Polymorphisms, Hepatic Steatosis and Lipid Anomalies in Diabetic Patients.
prise de sang; magnetic resonance imaging and magnetic resonance spectroscopy

Type 2 Diabetes Mellitus Clinical Trial using lixisenatide AVE0010; biguanide; TZD; alpha-GI; glinide

Sanofi - Recruiting 20 years or older.
- An Open-Label, Multicenter 52-Week Study Assessing the Safety and Tolerability of Lixisenatide in Combination With Oral Anti-Diabetic Treatment in Patients With Type 2 Diabetes.
lixisenatide AVE0010; biguanide; TZD; alpha-GI; glinide

Islet Transplantation in Diabetes Mellitus Type 1, Clinical Trial using Reparixin; Placebo

Domp‚ s.p.a. - Recruiting 18 years to 70 years.
- A Phase 3, Multicenter, Randomized, Double-blind, Parallel Assignment Study to Assess the Efficacy and Safety of Reparixin in Pancreatic Islet Transplantation.
Reparixin; Placebo

Type 1 Diabetes Clinical Trial using Metformin; Placebo

T1D Exchange Clinic Network Coordinating Center - Recruiting 12 years to 19 years.
- Metformin Therapy for Overweight Adolescents With Type 1 Diabetes (T1D)--Insulin Clamp Ancillary Study for Assessment of Insulin Resistance.
Metformin; Placebo

Diabetes Mellitus, Type 2 Clinical Trial

Ohio State University - Recruiting 40 years to 60 years.
- Leukocyte Dysfunction in Diabetic Patients..

Non-healing Wounds, or Diabetes Clinical Trial using Blood draw

Ohio State University - Recruiting 25 years to 80 years.
- Mechanisms Underlying Impaired Diabetic Wound Healing.
Blood draw

Type 2 Diabetes Clinical Trial using fotonovela

University of California, San Francisco - Recruiting 18 years or older.
- Utility of a Diabetes Themed Fotonovela to Encourage Glycemic Control: a Culturally Appropriate Tool for Education in Latinos.
fotonovela

Diabetes, or Pre-diabetes Clinical Trial using Weight loss and exercise training

University of Colorado, Denver - Recruiting 30 years to 60 years.
- Weight Loss and/or Exercise Training to Discover Muscle Lipids Related to Insulin Sensitivity..
Weight loss and exercise training

Diabetes, Metabolic Syndrome, or Insulin Resistance Clinical Trial using pegvisomant

University of California, San Francisco - Recruiting 18 years to 80 years.
- Role of Growth Hormone Antagonism in Modulating Insulin Sensitivity in Subjects With Insulin Resistance But Without Diabetes.
pegvisomant

Diabetes, or Diabetes Mellitus, Type 1 Clinical Trial using insulin aspart (faster acting insulin aspart); insulin aspart

Novo Nordisk - Recruiting 18 years to 64 years.
- A Trial Investigating the Pharmacodynamic Response of FIAsp in Subjects With Type 1 Diabetes.
insulin aspart (faster acting insulin aspart); insulin aspart

Heart Failure Clinical Trial using BAY94-8862; Placebo; Inspra (eplerenone)

Bayer - Recruiting 18 years or older.
- A Randomized, Double-blind, Double-dummy, Multi-center Study to Assess Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Emergency Presentation at the Hospital Because of Worsening Chronic Heart Failure With Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone Versus Eplerenone.
BAY94-8862; Placebo; Inspra (eplerenone)

Obesity, or Diabetes Clinical Trial using BYETTA treatment; Metformine

Assistance Publique Hopitaux De Marseille - Recruiting 18 years or older.
- Effect of GLP-1 Receptor (GLP-1R) Agonists on Cardiac Function and on Epicardial Adipose Tissue (EAT) Volume and on Myocardial TG Content in Obese Diabetics.
BYETTA treatment; Metformine

Diabetes Mellitus, Type 2 Clinical Trial using INSULIN GLARGINE (HOE901); INSULIN GLULISINE (HMR1964)

Sanofi - Recruiting 21 years or older.
- A Comparative Study to Evaluate the Prandial Treatment Adjustment Effect Via Continuous Glucose Monitoring on Type 2 DM Patients Uncontrolled With a Basal Insulin or Premix Once a Day.
INSULIN GLARGINE (HOE901); INSULIN GLULISINE (HMR1964)

Arterial Hypertension, or Diabetes Mellitus Clinical Trial using Conventional Holter monitoring; Implantable loop recorder

Odense University Hospital - Recruiting 65 years to 90 years.
- Detection of Subclinical Atrial Fibrillation in High Risk Patients (> 65 Years, Hypertension, Diabetes Mellitus) Using Implantable Loop Recorder.
Conventional Holter monitoring; Implantable loop recorder

Type 2 Diabetes Mellitus Clinical Trial using Dulaglutide; Glimepiride; Placebo

Eli Lilly and Company - Recruiting 18 years or older.
- The Efficacy and Safety of Once-Weekly, Subcutaneous Dulaglutide Monotherapy Compared to Glimepiride in Patients With Type 2 Diabetes Mellitus.
Dulaglutide; Glimepiride; Placebo

Overweight, Obesity, Type 2 Diabetes Mellitus Clinical Trial using AZP-531

Aliz‚ Pharma - Recruiting 18 years to 50 years.
- A Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZP-531 in Healthy Volunteers, Overweight/Obese Volunteers and Patients With Type 2 Diabetes Mellitus.
AZP-531

Type 2 Diabetes Mellitus Clinical Trial using Insulin Lispro Mix25; Insulin Lispro Mix50

Eli Lilly and Company - Recruiting 18 years or older.
- Comparison Between Low Mixed Insulin and Mid Mixed Insulin AS Starter Insulin For Patients With TYpe 2 Diabetes Mellitus (CLASSIFY Study).
Insulin Lispro Mix25; Insulin Lispro Mix50

Diabetes Mellitus, Type I, Diabetes Mellitus, Insulin-Dependent, Clinical Trial using Imatinib Mesylate; Placebo (For imatinib mesylate)

University of California, San Francisco - Recruiting 18 years to 45 years.
- Safety and Efficacy of Imatinib for Preserving Beta-Cell Function in New-Onset Type 1 Diabetes Mellitus.
Imatinib Mesylate; Placebo (For imatinib mesylate)

Type 1 Diabetes Mellitus Clinical Trial

UMC Utrecht - Recruiting 18 years or older.
- Ovarian Ageing in Type 1 Diabetes Mellitus: the Role of Vascular Factors.

Type 2 Diabetes Mellitus Clinical Trial using LY3053102; Exenatide extended release; Placebo

Eli Lilly and Company - Recruiting 21 years or older.
- Safety, Tolerability, Pharmacokinetics, and Efficacy of LY3053102 With 12 Weeks of Treatment in Patients With Type 2 Diabetes Mellitus.
LY3053102; Exenatide extended release; Placebo

Cystic Fibrosis Related Diabetes, or Cystic Fibrosis Clinical Trial

Children's Hospital of Philadelphia - Recruiting 6 years or older.
- Effects of Ivacaftor (Kalydeco) Treatment Upon Insulin and Incretin Secretion in Patients With Cystic Fibrosis.

Chronic Renal Insufficiency, or Diabetes Mellitus Clinical Trial using Sodium bicarbonate; Placebo

Department of Veterans Affairs - Recruiting 18 years or older.
- Investigations of the Optimum Serum Bicarbonate Level in Renal Disease.
Sodium bicarbonate; Placebo

Cardiovascular Disease, Hypertension, Diabetes, or Hyperlipidemia Clinical Trial using Pharmacist CVD

Department of Veterans Affairs - Recruiting N/A or older.
- Cardiovascular Intervention Improvement Telemedicine Study.
Pharmacist CVD

Type 2 Diabetes Mellitus Clinical Trial using LY2605541; Insulin Glargine

Eli Lilly and Company - Recruiting 20 years or older.
- A Phase 3, Open Label, Randomized, Parallel, 26 Week Treatment Study Comparing LY2605541 With Insulin Glargine as Basal Insulin Treatment in Combination With Oral Anti Hyperglycemia Medications in Asian Insulin Na‹ve Patients With Type 2 Diabetes Mellitus.
LY2605541; Insulin Glargine

Type-2 Diabetes Mellitus, or Coronary Artery Disease Clinical Trial using Ticagrelor + Aspirin; Clopidogrel + Aspirin

Mount Sinai School of Medicine - Recruiting 18 years to 75 years.
- Comparative Study of the Antithrombotic Effects of Ticagrelor and Clopidogrel in Type 2 Diabetic Patients.
Ticagrelor + Aspirin; Clopidogrel + Aspirin

Obesity, Insulin Resistance, or Diabetes Clinical Trial using Every Little Step Counts Intervention

Arizona State University - Recruiting 14 years to 16 years.
- Community-Based Diabetes Prevention Program for Obese Latino Youth: Every Little Step Counts.
Every Little Step Counts Intervention

Type 2 Diabetes Clinical Trial using High intensity interval training

German Diabetes Center - Recruiting 30 years to 65 years.
- Effect of High-intensity Low-volume Training on Insulin Sensitivity in Patients With Type 2 Diabetes and Healthy Lean Subjects.
High intensity interval training

Type 2 Diabetes Mellitus, or Iron Deficiency Clinical Trial using ferric carboxymaltose; NaCl (0,9%)

GWT-TUD GmbH - Recruiting 18 years or older.
- Intravenous Ferric Carboxymaltose for Improvement of Metabolic Parameters and Vascular Function in T2DM-patients With Iron Deficiency.
ferric carboxymaltose; NaCl (0,9%)

Acute Ischemic Stroke, Diabetes, or Hyperglycemia Clinical Trial using IV insulin to maintain target glucose concentration of 80-130 mg/dL; Standard Care control - sliding scale insulin to keep glucose less than 180 mg/dL

University of Virginia - Recruiting 18 years or older.
- Stroke Hyperglycemia Insulin Network Effort (SHINE) Trial.
IV insulin to maintain target glucose concentration of 80-130 mg/dL; Standard Care control - sliding scale insulin to keep glucose less than 180 mg/dL

Type 2 Diabetes, or Comparative Effectiveness of Glycemia-lowerin Clinical Trial using Sulfonylurea (glimepiride); DPP-4 inhibitor (sitagliptin); GLP-1 receptor agonist (liraglutide); Insulin (glargine)

GRADE Study Group - Recruiting 30 years or older.
- Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study.
Sulfonylurea (glimepiride); DPP-4 inhibitor (sitagliptin); GLP-1 receptor agonist (liraglutide); Insulin (glargine)

Diabetes Mellitus, or Type 2 Diabetes Clinical Trial using Sitagliptin; Metformin; Placebo to sitagliptin; Placebo to metformin

Merck Sharp & Dohme Corp. - Recruiting 10 years to 17 years.
- A Phase III, Multicenter, Double-Blind, Randomized, Placebo and Metformin-Controlled Clinical Trial to Evaluate the Safety and Efficacy of Sitagliptin in Pediatric Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control.
Sitagliptin; Metformin; Placebo to sitagliptin; Placebo to metformin

Type 2 Diabetes Mellitus Clinical Trial using MK-3012; Matching placebo to MK-3012; Glimepiride; Matching placebo to glimepiride; Insulin glargine; Metformin

Merck Sharp & Dohme Corp. - Recruiting 18 years or older.
- A Multicenter, Randomized, Double-Blind Study to Evaluate the Safety, Tolerability, and Efficacy of the Addition of MK-3102 to Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Therapy.
MK-3012; Matching placebo to MK-3012; Glimepiride; Matching placebo to glimepiride; Insulin glargine; Metformin

Chronic Liver Disease, Hazardous Alcohol Use, Type 2 Diabetes, or Clinical Trial using Fibrosis Biomarkers

University of Nottingham - Recruiting 18 years or older.
- The Stratification of Liver Disease in the Community Using Fibrosis Biomarkers.
Fibrosis Biomarkers

Type 2 Diabetes Mellitus Clinical Trial using Low Glycemic Index (LGI) intervention arm; Standard Diet Intervention

National University Hospital, Singapore - Recruiting 45 years to 64 years.
- Nutrition Studies and Dietary Intervention in Individuals With Type 2 Diabetes Mellitus of Chinese, Malay and Indian Ethnicity.
Low Glycemic Index (LGI) intervention arm; Standard Diet Intervention

Type 1 Diabetes Mellitus Clinical Trial using LY2605541; Insulin Glargine

Eli Lilly and Company - Recruiting 18 years to 60 years.
- Evaluation of the Effects of LY2605541 on Respiratory Quotient During Sleep and Response to Hyperinsulinemia Compared With That of Insulin Glargine in Patients With Type 1 Diabetes Mellitus.
LY2605541; Insulin Glargine

Type 2 Diabetes, or Cardiovascular Disease Clinical Trial using Sitagliptin; Glimepiride; Placebo

University of Colorado, Denver - Recruiting 22 years to 70 years.
- Impact of Sitagliptin on Cardiovascular Exercise Performance in Type 2 Diabetes.
Sitagliptin; Glimepiride; Placebo

Sleep Apnea, Central, Sleep Disordered Breathing, or Heart Failur Clinical Trial using Treatment Group (remede; phrenic nerve stimulation); Control Group (Optimal Medical Therapy)

Respicardia, Inc. - Recruiting 18 years or older.
- A Randomized Trial Evaluating the Safety and Effectiveness of the Remede System in Patients With Central Sleep Apnea.
Treatment Group (remede; phrenic nerve stimulation); Control Group (Optimal Medical Therapy)

Diabetes Mellitus, Cardiovascular Disease, Healthy Volunteer, or Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- Inflammatory Characterization of Known or Possible Cardiovascular Diseases.

Type 2 Diabetes Clinical Trial

AstraZeneca - Recruiting N/A or older.
- Specific Clinical Experience Investigation for Long-term Use of Bydureon Subcutaneous Injection 2 mg.

Atrial Fibrillation, Stroke, Hypertension, or Diabetes Clinical Trial using LOOP recorder (Medtronic LINQ device)

Rigshospitalet, Denmark - Recruiting 70 years to 90 years.
- Atrial Fibrillation Detected by Continuous ECG Monitoring Using Implantable Loop Recorder to Prevent Stroke in High-risk Individuals..
LOOP recorder (Medtronic LINQ device)

Diabetes, or Diabetes Mellitus, Type 1 Clinical Trial using insulin aspart (FIAsp); insulin aspart

Novo Nordisk - Recruiting 6 years to 64 years.
- A Trial Investigating the Pharmacokinetic Properties of FIAsp in Children, Adolescents and Adults With Type 1 Diabetes.
insulin aspart (FIAsp); insulin aspart

Diabetes Mellitus Clinical Trial using AgaMatrix Blood Glucose Monitor

AgaMatrix, Inc. - Recruiting 18 years or older.
- User Study for the Evaluation of an Enhanced Meter Feature Using an AgaMatrix BGMS.
AgaMatrix Blood Glucose Monitor

Diabetes, Heart Disease, or Asthma Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- Environmental Polymorphisms Registry Health and Exposures Survey.

Liver Cirrhosis Clinical Trial

Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico - Recruiting 18 years to 65 years.
- Insulin Secretion and Sensitivity in Subjects With Liver Cirrhosis Undergoing Orthotopic Liver Transplantation (OLT): Pre- and Post-OLT Analysis.

Type 1 Diabetes Clinical Trial using ePID closed loop system; InsuPatch

Yale University - Recruiting 12 years to 40 years.
- Effect of the Insupatch on Automated Closed-loop Glucose Control in Type 1 Diabetes.
ePID closed loop system; InsuPatch

Type 2 Diabetes Clinical Trial

AstraZeneca - Recruiting N/A or older.
- Specific Clinical Experience Investigation for Long-term Use of Exenatide (Byetta Subcutaneous Injection).

Diabetic Foot Ulcers Clinical Trial using Gentamicin Topical Gel; Ciprofloxacin; Doxycycline

Royer Biomedical, Inc. - Recruiting 18 years or older.
- A Phase I/II, Open Label, Controlled Study to Evaluate the Safety and Efficacy of AppliGel-G [Gentamicin Sulfate Topical Gel] for Treatment of Mild to Moderately Infected Diabetic Foot Ulcers in Patients With Type 1 and Type 2 Diabetes.
Gentamicin Topical Gel; Ciprofloxacin; Doxycycline

Diabetic Nephropathy Clinical Trial using PF-04634817; Placebo

Pfizer - Recruiting 18 years or older.
- A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center Study To Evaluate The Efficacy And Safety Of Once-Daily Administration Of A Chemokine CCR2/5 Receptor Antagonist (PF-04634817) In Adults With Type 2 Diabetes And Overt Nephropathy.
PF-04634817; Placebo

Type 2 Diabetes Clinical Trial using Lifestyle counseling with smartphone; Lifestyle counseling

York University - Recruiting 18 years to 75 years.
- Electronically Connected Health Coaching in Improving Type 2 Diabetes Self Management - Phase III Trial.
Lifestyle counseling with smartphone; Lifestyle counseling

Kidney; Complications, Allograft Clinical Trial using Everolimus; Tacrolimus; Mycophenolic acid

Seoul St. Mary's Hospital - Recruiting 20 years or older.
- To Evaluate Prevention Effect Of Everolimus and Low-dose Tacrolimus in Comparison With Standard-dose Tacrolimus Therapy With Mycophenolic Acid on the New Onset Diabetes Mellitus After Transplantation in the Renal Allograft Recipients.
Everolimus; Tacrolimus; Mycophenolic acid

Diabetes Mellitus Clinical Trial using Mobile Insulin Titration Intervention

New York University School of Medicine - Recruiting 18 years to 70 years.
- The Mobile Insulin Titration Intervention (MITI) Pilot Project: Time-saving Scale-up of Diabetic Best Practices to Efficiently Reach Optimal Glycemic Control.
Mobile Insulin Titration Intervention

Diabetic Nephropathy Clinical Trial using colchicine 0.5mg/d; placebo 0.5mg/d

Chongqing Medical University - Recruiting 30 years to 70 years.
- Low-dose Colchicine Intervention in Patients With Type 2 Diabetes Mellitus and Microalbuminuria: Chongqing Study.
colchicine 0.5mg/d; placebo 0.5mg/d

Prevention of New Onset Diabetes Among Kidney Transplant Patients Clinical Trial using Insulin treatment for hyperglycemia

University of Michigan - Recruiting 18 years or older.
- A Clinical Trial to Prevent New Onset Diabetes After Transplantation.
Insulin treatment for hyperglycemia

Diabetes, or Diabetes Mellitus, Type 2 Clinical Trial using liraglutide; metformin; sulfonylurea

Novo Nordisk - Recruiting 18 years or older.
- Efficacy and Safety of Liraglutide Versus Sulphonylurea Both in Combination With Metformin During Ramadan in Subjects With Type 2 Diabetes.
liraglutide; metformin; sulfonylurea

Diabetes, Diabetes Mellitus, Type 2, or Healthy Clinical Trial using semaglutide

Novo Nordisk - Recruiting 18 years to 85 years.
- Investigation of Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects With Various Degrees of Impaired Renal Function Compared to Subjects With Normal Renal Function.
semaglutide

Type 2 Diabetes, or Oxidative Stress Clinical Trial using ascorbic acid (Vitamin C)

University of Kansas - Recruiting 30 years to 55 years.
- Quantitative in Vivo Biomarkers of Oxidative Stress in Diabetes.
ascorbic acid (Vitamin C)

Diabetes Mellitus, Type 1 Clinical Trial using Intranasal Glucagon; Glucagon

T1D Exchange Clinic Network Coordinating Center - Recruiting 4 years to 16 years.
- Assessment of Intranasal Glucagon in Children and Adolescents With Type 1 Diabetes.
Intranasal Glucagon; Glucagon

Type 2 Diabetes Mellitus Clinical Trial using LAF237 50 mg; Placebo

Novartis - Recruiting 20 years to 74 years.
- A 12-week, Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of Equa (Vildagliptin) 50 mg Bid as an add-on Therapy to Insulin, With or Without Metformin, in Patients With Type 2 Diabetes Mellitus.
LAF237 50 mg; Placebo

Emotional Distress, Type 2 Diabetes, or Stress Clinical Trial using Mindfulness Based Stress Reduction

University of North Carolina, Chapel Hill - Recruiting 30 years or older.
- Mindfulness: a Novel Approach for the Management of Diabetes-related Distress.
Mindfulness Based Stress Reduction

Diabetes, or Diabetes Mellitus, Type 2 Clinical Trial using insulin aspart (FIAsp); basal insulin

Novo Nordisk - Recruiting 18 years or older.
- Efficacy and Safety of FIAsp in a Basal-bolus Regimen Versus Basal Insulin Therapy, Both in Combination With Metformin in Adult Subjects With Type 2 Diabetes.
insulin aspart (FIAsp); basal insulin

Diabetes Mellitus (DM), Congestive Heart Failure (CHF), or Chroni Clinical Trial using Community Paramedicine; Usual Care

St. Michael's Hospital, Toronto - Recruiting 18 years or older.
- The Expanding Paramedicine in the Community (Study).
Community Paramedicine; Usual Care

Diabetes Mellitus, Type 1, or Diabetes Mellitus, Type 2 Clinical Trial using Intranasal Glucagon; Glucagon

T1D Exchange Clinic Network Coordinating Center - Recruiting 18 years to 64 years.
- Efficacy and Safety of Intranasal Glucagon for Treatment of Insulin Induced Hypoglycemia in Adults With Diabetes.
Intranasal Glucagon; Glucagon

Type 2 Diabetes Mellitus Clinical Trial using Ursodiol

Mayo Clinic - Recruiting 18 years to 70 years.
- Effect of Delayed-Release Ursodeoxycholic Acid on Insulin Sensitivity, Gastric Emptying and Body Weight in Overweight or Obese Patients With Type 2 Diabetes on Metformin Treatment.
Ursodiol

Diabetes Mellitus, or Lactic Acidosis Clinical Trial using Metformin

Shahid Beheshti Medical University - Recruiting N/A or older.
- Incidence of Lactic Acidosis After Coronary Angiography and Angioplasty in Diabetic Patients on Continued Metformin Therapy With Normal Renal Function..
Metformin

Diabetes Mellitus, Type 2 Clinical Trial using PL2200 Aspirin Capsules; Enteric-coated aspirin caplets

PLx Pharma - Recruiting 21 years to 79 years.
- Reliable Inhibition of Thrombocyte Activity: Comparison of PL2200 Aspirin Capsules, 325 mg and Enteric-Coated Aspirin (RITE Study).
PL2200 Aspirin Capsules; Enteric-coated aspirin caplets

Diabetes Mellitus, Type 2 Clinical Trial using Placebo - Capsule; LY3108743 - Capsule; Placebo - Solution; LY3108743 - Solution

Eli Lilly and Company - Recruiting 21 years to 65 years.
- Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Oral Doses of LY3108743 in Healthy Subjects and Patients With Type 2 Diabetes Mellitus.
Placebo - Capsule; LY3108743 - Capsule; Placebo - Solution; LY3108743 - Solution

Diabetes, Type I, Diabetes, Type II, Angina, or Coronary Artery D Clinical Trial using Ranolazine; Placebo Pill

Brigham and Women's Hospital - Recruiting 18 years to 90 years.
- Effects of Ranolazine on Coronary Flow Reserve in Symptomatic Patients With Diabetes and Suspected or Known Coronary Artery Disease.
Ranolazine; Placebo Pill

Chronic Pain, Diabetic Neuropathies, or Diabetes Mellitus Clinical Trial using Cebranopadol 100 æg; Cebranopadol 300 æg; Cebranopadol 600 æg; Pregabalin; Matching Placebo

Grnenthal GmbH - Recruiting 18 years to 80 years.
- Efficacy, Safety and Tolerability of Multiple Doses of Oral Cebranopadol in Subjects With Moderate to Severe Chronic Pain Due to Diabetic Peripheral Neuropathy..
Cebranopadol 100 æg; Cebranopadol 300 æg; Cebranopadol 600 æg; Pregabalin; Matching Placebo

Type 2 Diabetes Mellitus (T2DM) Clinical Trial using PE0139 Injection; Placebo

PhaseBio Pharmaceuticals Inc. - Recruiting 18 years to 65 years.
- Phase 1 Multicenter, Randomized, Double-Blind, Placebo Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Response of PE0139 Injection in Adult Subjects With Type 2 Diabetes Mellitus.
PE0139 Injection; Placebo

Diabetes Mellitus Type 1 Clinical Trial using BioChaperone insulin lispro; Humalogr

Adocia - Recruiting 18 years to 64 years.
- A Double-blinded, Randomised, Two -Period Crossover Euglycemic Clamp Trial Investigating the Pharmacokinetics, Glucodynamics and Safety of BioChaperone Insulin Lispro and Insulin Lispro (Humalogr) in Subjects With Type 1 Diabetes.
BioChaperone insulin lispro; Humalogr

Diabetes Clinical Trial using SMS MESSAGING

Basque Health Service - Recruiting 35 years to 74 years.
- Effectiveness of Sending Sms Text Messages to Mobile Phone Patients to Remind Upcoming Appointments and Improve the Control of Diabetic Patients in Primary Care.
SMS MESSAGING

Overweight, or Diabetes Mellitus Type 2 in Obese Clinical Trial using P11187; Placebo

Piramal Enterprises Limited - Recruiting 18 years to 70 years.
- A Phase I, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Safety, Tolerability, Pharmacokinetics, Food Effect and Pharmacodynamics of Single and Multiple Ascending Doses of P11187.
P11187; Placebo

Obesity, Insulin Resistance, Triglycerides, or Diabetes Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 30 years to 65 years.
- Identifying Risk for Diabetes and Heart Disease in Women: A Study of African-American, African and White Federal Employees and Contractors.

Type 2 Diabetes Clinical Trial using High intensity aerobic interval training; Continuous moderate intensity exercise

University of Florida - Recruiting 30 years to 79 years.
- Mechanisms of Cardiovascular Dysfunction and Effect of Aerobic Exercise Training in Adults With Type 2 Diabetes.
High intensity aerobic interval training; Continuous moderate intensity exercise

Type 2 Diabetes Mellitus With Diabetic Nephropathy Clinical Trial using GKT137831; Placebo

Genkyotex Innovation SAS - Recruiting 18 years to 80 years.
- A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Study Evaluating the Safety and Efficacy of Oral GKT137831 in Patients With Type 2 Diabetes and Albuminuria.
GKT137831; Placebo

Type 2 Diabetes Clinical Trial using CMR

Wuhan General Hospital of Guangzhou Military Command - Recruiting 30 years to 65 years.
- Impact of Cardiac Magnetic Resonance Imaging on Endothelial Function in Type 2 Diabetes.
CMR

Diabetes Mellitus, Type 2 Clinical Trial using INSULIN GLARGINE; Metformin; DPP-4 inhibitor; Sulphonylurea

Sanofi - Recruiting 20 years or older.
- Efficacy and Safety of TrEating Type 2 Diabetic Patients With Inadequate Response to Metformin and DPP-4 Inhibitors by Adding Basal Insulin Therapy (Insulin Glargine).
INSULIN GLARGINE; Metformin; DPP-4 inhibitor; Sulphonylurea

Cardiovascular Disease, Diabetes, or Metabolic Syndrome Clinical Trial

University of Manitoba - Recruiting 20 years to 65 years.
- Effects of Oleic Acid Enriched and Regular Canola Oil on Body Composition and Lipid Metabolism in Participants With Metabolic Syndrome.

Type 2 Diabetes or Obesity Without Diabetes Clinical Trial using Measure the threshold of detection for linoleic acid; Oral stimulation tests; Venous blood samples; Samples for genetic studies (ancillary study)

Centre Hospitalier Universitaire Dijon - Recruiting 18 years or older.
- Search for Biological Markers of Orosensory Perception of Fatty Acids in Healthy Subjects and Possible Modifications in Patients With Type 2 Diabetes and in Obese Non-diabetic Patients..
Measure the threshold of detection for linoleic acid; Oral stimulation tests; Venous blood samples; Samples for genetic studies (ancillary study)

Diabetic Nephropathy Clinical Trial using Atrasentan; Placebo

AbbVie - Recruiting 18 years to 85 years.
- A Randomized, Multicountry, Multicenter, Double-Blind, Parallel, Placebo-Controlled Study of the Effects of Atrasentan on Renal Outcomes in Subjects With Type 2 Diabetes and Nephropathy SONAR: Study Of Diabetic Nephropathy With Atrasentan.
Atrasentan; Placebo

Type 2 Diabetes Clinical Trial using LEHEL multi-nutrients supplement

Shaoguan University - Recruiting 25 years to 75 years.
- Metabolic Control Before and After Supplementation With LEHEL in Patients With Type 2 Diabetes.
LEHEL multi-nutrients supplement

Diabetes, Diabetes Mellitus, Type 2, or Healthy Clinical Trial using semaglutide; placebo; metformin; warfarin

Novo Nordisk - Recruiting 18 years to 55 years.
- An Open-label, One-sequence Cross Over, Single Centre Trial, Investigating the Influence of Semaglutide on Pharmacokinetics and Pharmacodynamics of Warfarin and Pharmacokinetics of Metformin in Healthy Subjects.
semaglutide; placebo; metformin; warfarin

Diabetes, or Diabetes Mellitus, Type 2 Clinical Trial using insulin degludec/liraglutide; insulin glargine

Novo Nordisk - Recruiting 18 years or older.
- A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide Versus Insulin Glargine in Subjects With Type 2 Diabetes Mellitus (DUALTM V - Basal Insulin Switch).
insulin degludec/liraglutide; insulin glargine

Type 2 Diabetes, or Hypogonadism Clinical Trial using Testosterone

Tameside Hospital NHS Foundation Trust - Recruiting 50 years to 80 years.
- Phase IV: Effect of Testosterone on Endothelial Function and Microcirculation in Type 2 Diabetic Patients With Hypogonadism.
Testosterone

Diabetes, or Depression Clinical Trial using Behavioral activation (BA)

Providence VA Medical Center - Recruiting 18 years or older.
- Behavioral Activation Therapy for Both Depression and Diabetes Vs. Diabetes Alone Delivered Via Group Visits.
Behavioral activation (BA)

Diabetes, or Gestational Clinical Trial using Insulin; Glyburide

Assistance Publique - H“pitaux de Paris - Recruiting 18 years to 45 years.
- Multicenter Randomized Trial of Non-inferiority Between Glyburide and Insulin for the Treatment of Gestational Diabetes.
Insulin; Glyburide

Type 2 Diabetes Clinical Trial using Vitamin D3 Supplementation

National Institutes of Health Clinical Center (CC) - Recruiting 30 years or older.
- Vitamin D and Type 2 Diabetes (Phoenix Site).
Vitamin D3 Supplementation

Diabetes Mellitus, Type 2 Clinical Trial using glimepiride; glargine and metformin

Chongqing Medical University - Recruiting 35 years to 70 years.
- Efficacy/Safety Study of Adding Glimepiride to Type 2 Diabetes Patients With Inadequate Glycemic Control Based on Combination With Metformin And Basal Insulin.
glimepiride; glargine and metformin

Diabetes Mellitus, Insulin-Dependent, or Type 1 Clinical Trial using Oshadi Icp

Oshadi Drug Administration - Recruiting 21 years or older.
- A Single Center, Multiple-dose, Non-randomized, Dose Adjustment, Open-Label Study to Evaluate the Efficacy, Pharmacodynamics, Safety, and Tolerability of Oshadi Icp in Patients With Type 1 Diabetes Mellitus -A Phase II Clinical Study.
Oshadi Icp

Myocardial Ischemia, Autonomic Neuropathy, Healthy, or Diabetes Clinical Trial

VU University Medical Center - Recruiting 18 years to 75 years.
- Cardiac Sympathetic Innervation and Coronary Blood Flow Regulation During General Anesthesia.

Type 1 Diabetes Clinical Trial using Metformin; Placebo

University of Colorado, Denver - Recruiting 12 years to 19 years.
- Effects of Metformin on Cardiovascular Function in Adolescents With Type 1 Diabetes.
Metformin; Placebo

Type 2 Diabetes, Coronary Artery Disease, or Left Ventricular Mas Clinical Trial using alpha-lipoic acid

Wuhan General Hospital of Guangzhou Military Command - Recruiting 40 years to 70 years.
- Alpha-lipoic Acid Reduces Left Ventricular Mass in Normotensive Type 2 Diabetic Patients With Coronary Artery Disease.
alpha-lipoic acid

Polycystic Ovary Syndrome Clinical Trial using Moxonidine; Placebo

Baker IDI Heart and Diabetes Institute - Recruiting 18 years to 45 years.
- Polycystic Ovary Syndrome - Targeting the Sympathetic Nervous System to Improve Outcomes.
Moxonidine; Placebo

Diabetes, Diabetes Mellitus, Type 2, or Healthy Clinical Trial using semaglutide

Novo Nordisk - Recruiting 18 years to 85 years.
- Investigation of Pharmacokinetics, Safety and Tolerability of Oral Semaglutide (NNC0113-0217) in Subjects With Mild, Moderate and Severe Degrees of Hepatic Impairment Compared to Subjects With Normal Hepatic Function.
semaglutide

Metabolic Diseases, Type 2 Diabetes, Cardiovascular Disease Clinical Trial using Carnosine

Slovak Academy of Sciences - Recruiting 25 years to 50 years.
- Randomised Placebo Controlled Study of the Effect of Carnosine Diabetes and Cardiovascular Risk Factors.
Carnosine

Type 2 Diabetes, or Hypertension Clinical Trial using Individual treatment

Odense University Hospital - Recruiting 18 years or older.
- Individually Tailored Treatment of Type 2 Diabetes.
Individual treatment

Type 1 Diabetes Clinical Trial

University Medical Centre Ljubljana - Recruiting N/A to 7 years.
- The Influence of Diabetes Related Technology, Education and Psychological Support on Metabolic Control in Young Children With Type 1 Diabetes.

Diabetes Clinical Trial using Lifestyle Intervention

University of Massachusetts, Amherst - Recruiting 18 years to 45 years.
- Estudio PARTO: Proyecto pAra Reducir Diabetes Tipo dOs / Project Aiming to Reduce Type twO Diabetes.
Lifestyle Intervention

Diabetes Mellitus Clinical Trial using Microprobe glucose sensor

Imperial College London - Recruiting 18 years to 75 years.
- Clinical Assessment of a Novel Microprobe Array Continuous Glucose Monitor for Type 1 Diabetes.
Microprobe glucose sensor

Diabetes Mellitus Clinical Trial using MK-8521; Liraglutide; Placebo

Merck Sharp & Dohme Corp. - Recruiting 18 years to 69 years.
- A Phase Ib, Multicenter, Placebo and Active- Comparator-Controlled, Randomized, Double-Blind, Clinical Trial to Evaluate the Safety and Efficacy of MK-8521 Compared to Placebo and a Diabetes Drug in Subjects With Type 2 Diabetes Mellitus.
MK-8521; Liraglutide; Placebo

Type 1 Diabetes Clinical Trial using Carbohydrate-rich meal; Exercise

Institut de Recherches Cliniques de Montreal - Recruiting 12 years or older.
- An Open-label, Randomized, Three-way, Multicenter Study to Compare the Efficacy of Single-hormone Closed-loop Strategy, Dual-hormone Closed-loop Strategy and Conventional Insulin Pump Therapy in Regulating Overnight Glucose Levels at Home in Adolescents and Adults With Type 1 Diabetes.
Carbohydrate-rich meal; Exercise

Diabetes During Pregnancy Clinical Trial using NPH; Insulin LISPRO; Insulin glulisine

Sansum Diabetes Research Institute - Recruiting 18 years or older.
- Non-inferiority Trial Comparing Insulin Glulisine to Insulin Lispro as Part of a Basal-bolus Insulin Regimen for the Treatment of Gestational Diabetes..
NPH; Insulin LISPRO; Insulin glulisine

Diabetes Mellitus, Type 2, or Healthy Volunteers Clinical Trial using Dulaglutide; Placebo

Eli Lilly and Company - Recruiting 18 years to 75 years.
- Pharmacokinetics of a Single Dulaglutide Dose in Healthy Chinese Subjects and of Multiple Dulaglutide Doses in Chinese Patients With T2DM.
Dulaglutide; Placebo

Sub-optimal Vitamin D Status, Pre-diabetes, or Insulin Resistance Clinical Trial using Vitamin D3 supplementation

Queen's University, Belfast - Recruiting 18 years or older.
- Effect of Vitamin D3 Supplementation on Insulin Resistance and Cardiovascular Risk Factors in People at High Risk of Type 2 Diabetes and Cardiovascular Disease (The DIR Study).
Vitamin D3 supplementation

Metabolic Syndrome, Diabetes, or Aging Clinical Trial using US; IW; CW

University of Colorado, Denver - Recruiting 60 years to 85 years.
- Effects of Interrupting Sedentary Time on Glycemic Control in Older Overweight and Obese Adults.
US; IW; CW

Type 2 Diabetes Clinical Trial using Vitamin D; Placebo

University of Florida - Recruiting 30 years to 65 years.
- Effects of Treating Vitamin D Deficiency in Poorly Controlled Type 2 Diabetes.
Vitamin D; Placebo

Diabetes, or Pre-Diabetes Clinical Trial using water-soluble cinnamon extract (Cinnulin PF)

Mike O'Callaghan Federal Hospital - Recruiting 18 years or older.
- Cinnamon Trial-Assessment of the effeCt of lIfestyle iNtervention Plus Water-soluble ciNnAMon Extract On loweriNg Blood Glucose in Pre-diabetics: A Randomized, Double-blind, Multicenter, Placebo Controlled TRIAL..
water-soluble cinnamon extract (Cinnulin PF)

Cancer, Cardiovascular Disease, Diabetes, or Non Communicable Chr Clinical Trial

Yale University - Recruiting 40 years or older.
- Eastern Caribbean Health Outcomes Research Network (ECHORN).

Type 1 Diabetes, or Type 2 Diabetes Clinical Trial using Medtronic MiniMed 620G or 640G Insulin Pump

Medtronic Diabetes - Recruiting 7 years or older.
- A User Evaluation of the MiniMedr 620G and 640G Insulin Pumps and Guardianr Link Transmitter.
Medtronic MiniMed 620G or 640G Insulin Pump

Type 1 Diabetes, or Eating Disorder Clinical Trial

Park Nicollet Institute - Recruiting 12 years or older.
- Development of an Instrument to Screen for Eating Disorder Symptoms in Persons With Type 1 Diabetes.

Diabetes, or Diabetes Mellitus, Type 1 Clinical Trial using BioChaperoner Combo; Humalogr Mix25

Adocia - Recruiting 18 years to 64 years.
- Phase 1 Study to Assess the Efficacy and Safety of BioChaperoner Combo and Humalogr Mix 25 in Subjects With Type 1 Diabetes.
BioChaperoner Combo; Humalogr Mix25

Diabetic Neuropathy, or Cognitive Impairment Clinical Trial using Tocotrienol; Placebo

University of Science Malaysia - Recruiting 20 years or older.
- A Clinical Study on the Neuroprotection by Tocotrienols in Type 1 and Type 2 Diabetes Mellitus.
Tocotrienol; Placebo

Type 2 Diabetes Clinical Trial using Red Grape Cells (RGC); Placebo (for Red Grape Cells (RGC))

Tel Aviv University - Recruiting 30 years to 70 years.
- Effects of Red Grape Cells (RGC) Powder on Glycemic and Lipid Control in Patients With Type 2 Diabetes ª A Double-blind, Randomized, Placebo Controlled Study.
Red Grape Cells (RGC); Placebo (for Red Grape Cells (RGC))

Type 2 Diabetes Clinical Trial using Sitagliptin + glargine; Basal Bolus; Metformin and sitagliptin; Metformin and sitagliptin + glargine 50%; Metformin and sitagliptin + glargine 80%

Emory University - Recruiting 18 years to 80 years.
- Randomized Controlled Trial on the Safety and Efficacy of Sitagliptin Therapy for the Inpatient Management of General Medicine and Surgery Patients With Type 2 Diabetes.
Sitagliptin + glargine; Basal Bolus; Metformin and sitagliptin; Metformin and sitagliptin + glargine 50%; Metformin and sitagliptin + glargine 80%

Diabetes, or Diabetes Mellitus, Type 2 Clinical Trial using liraglutide; lixisenatide

Novo Nordisk - Recruiting 18 years or older.
- Efficacy and Safety of Liraglutide Versus Lixisenatide as add-on to Metformin in Subjects With Type 2 Diabetes.
liraglutide; lixisenatide

Obesity, Diabetes, Hypertension, or Asthma/COPD With Tobacco Depe Clinical Trial using CHW Goal Support

University of Pennsylvania - Recruiting N/A or older.
- Community Health Worker Support to Help Patients Control Chronic Disease.
CHW Goal Support

Diabetes Mellitus Type 2, or Obesity Clinical Trial using Behavioural change programme

Norwegian University of Science and Technology - Recruiting 18 years to 65 years.
- The VEND RISK-study. Preventing Diabetes Type 2 in Overweight Persons in the V‘rnes Region, Central-Norway..
Behavioural change programme

Insulin Resistance, or Chronic Heart Failure Clinical Trial using Metformini hydrochloridum (Siofor 1000 tbl, Berlin); placebo

Institute for Clinical and Experimental Medicine - Recruiting 40 years to 70 years.
- Cardioprotective and Metabolic Effects of Metformin in Patients With Heart Failure and Diabetes.
Metformini hydrochloridum (Siofor 1000 tbl, Berlin); placebo

Type 2 Diabetes Mellitus, or Cardiovascular Disease Clinical Trial using Saxagliptin

Duke University - Recruiting 45 years to 75 years.
- Mechanistic Assessment of the Properties of Saxagliptin in Subjects Undergoing Coronary Artery Bypass Graft Surgery: a Randomized, Double-Blind, Placebo-Controlled Clinical Trial.
Saxagliptin

Excessive Weight Gain in Pregnancy as Antepartum Condition, Obesi Clinical Trial using Exercise and Nutrition Intervention

McMaster University - Recruiting 18 years or older.
- Be Healthy in Pregnancy (B-HIP): A Randomized Clinical Trial (RCT) to Study Nutrition and Exercise Approaches for Healthy Pregnancy.
Exercise and Nutrition Intervention

Type 2 Diabetes Clinical Trial using Dapagliflozin; Placebo matching with Dapagliflozin; Saxagliptin; Metformin immediate release (IR)

Bristol-Myers Squibb - Recruiting 18 years or older.
- A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Therapy With Dapagliflozin Added to Saxagliptin in Combination With Metformin Compared to Therapy With Placebo Added to Saxagliptin in Combination With Metformin in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin and Saxagliptin.
Dapagliflozin; Placebo matching with Dapagliflozin; Saxagliptin; Metformin immediate release (IR)

Polycystic Ovary Syndrome, or Obstructive Sleep Apnea Clinical Trial using Depot Lupron followed by estrogen plus placebo; Depot Lupron followed by progesterone plus placebo.; CPAP

University of Chicago - Recruiting 18 years to 40 years.
- PCOS, Sleep Apnea and Metabolic Risk in Women.
Depot Lupron followed by estrogen plus placebo; Depot Lupron followed by progesterone plus placebo.; CPAP

Obstructive Sleep Apnea (OSA) Clinical Trial using CPAP

University of Chicago - Recruiting 18 years to 40 years.
- Sleep and Metabolism in Obesity: Impact of Gender.
CPAP

Type 2 Diabetes Mellitus, or Nephropathy Clinical Trial using Valsartan; Placebo; Probucol

Guangdong General Hospital - Recruiting 30 years to 70 years.
- A Prospective Randomized, Controlled, Open-labeled Trial of Probucol Combined With Valsartan in Patients With Diabetes Nephropathy.
Valsartan; Placebo; Probucol

Diabetes Mellitus, Cigarette Smoking, or Prediabetes Clinical Trial using Smoking cessation; Self-management

National Taiwan University Hospital - Recruiting 30 years to 75 years.
- Community-based Pilot Study of the Effectiveness of Smoking Cessation for Prediabetes.
Smoking cessation; Self-management

Celiac Disease, or Diabetes Mellitus, Type 1 Clinical Trial using Gluten Free Diet

The Hospital for Sick Children - Recruiting 8 years to 35 years.
- A Randomized Controlled Trial to Evaluate the Efficacy and Safety of a Gluten-Free Diet in Patients With Asymptomatic Celiac Disease and Type 1 Diabetes, Celiac Disease and Diabetes - Dietary Intervention and Evaluation Trial (CD-DIET).
Gluten Free Diet

Diabetes Mellitus Type 1, or Retinal Branch Vein Occlusion Clinical Trial using COX inhibitor; L-NG-monomethyl arginine citrate; COX inhibitor + L-NG-monomethyl arginine citrate

University of Aarhus - Recruiting 20 years to 55 years.
- Diameter Changes of Retinal Vessels During Hypoxia.
COX inhibitor; L-NG-monomethyl arginine citrate; COX inhibitor + L-NG-monomethyl arginine citrate

Type 1 Diabetes Clinical Trial using ferumoxytol

Massachusetts General Hospital - Recruiting 18 years or older.
- Ferumoxytol Enhanced Magnetic Resonance Imaging of Type 1 Diabetes Progression.
ferumoxytol

Prediabetes, or Mild to Moderately High Severity of Depressive Sy Clinical Trial using Lifestyle Intervention; Structured and Guided Education

Duke University - Recruiting 30 years to 70 years.
- Mindfulness-based Personalized Health Planning for Reducing Risk Factors of Heart Disease and Diabetes.
Lifestyle Intervention; Structured and Guided Education

Type 2 Diabetes Clinical Trial using ITCA 650 60 mcg/day; sitagliptin

Intarcia Therapeutics - Recruiting 18 years to 80 years.
- A Phase 3, Randomized, Active Comparator, Double-Blind, Multi-Center Study to Compare the Efficacy, Safety and Tolerability of ITCA 650 to Sitagliptin as Add-on Therapy to Metformin in Patients With Type 2 Diabetes.
ITCA 650 60 mcg/day; sitagliptin